Testosterone Enanthate Regret, Stopping, and Restarting: What Patients Actually Experience

What is documented about stopping

Regret is not an outcome reported in the label or the studies below. What is documented is narrower: the withdrawal picture the label describes, the side effects that show up in trials and on the label, and how long sperm take to come back.

The label's drug abuse and dependence section describes what can happen when testosterone is stopped abruptly in people taking supratherapeutic doses: withdrawal symptoms lasting weeks to months, including depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism [1]. The same section says drug dependence in people using approved doses for approved indications has not been documented [1].

One trial shows why healthy men stopped injections. In a contraception study, 271 healthy fertile men received 200 mg of testosterone enanthate weekly [4]. That schedule was more frequent than the label's every-2-to-4-week schedule [1]. Discontinuations there were mainly because azoospermia was not achieved within 6 months and because of dislike of the injection schedule [4].

Side effects and safety findings to watch after restarting

Hematocrit is the most consistently measured one. Across 29 placebo-controlled randomized trials (3,393 men), intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% versus placebo (95% CI 2.9 to 5.1) [3]. In a retrospective review of 178 hypogonadal men followed for three years, erythrocytosis (hematocrit above 50%) occurred in 66.7% of men on injectable testosterone versus 12.8% on gels and 35.1% on pellets; the injection group was younger and started with a higher baseline hematocrit, and the study was not randomized [5]. A separate review put the risk of erythrocytosis (hematocrit above 0.52) at 315% higher in men on testosterone replacement than in controls, with all formulations raising hematocrit and injectables raising it the most [6].

The enanthate label lists polycythemia among adverse reactions and carries a postmarketing warning about venous thromboembolism, including deep vein thrombosis and pulmonary embolism; if a VTE is suspected, the label says to discontinue treatment and start an appropriate workup [1].

Gynecomastia is the other change that can outlast the injections. The label says it frequently develops and occasionally persists in men treated for hypogonadism [1]. Most gynecomastia comes from deficient androgen action or excessive estrogen action in breast tissue; estrogens stimulate breast-tissue growth and androgens inhibit it [7]. Aromatase converts androgens to estrogens [8].

Lipids and injection-site reactions round out the list: the label lists increased serum cholesterol, injection site pain and inflammation, acne, and warns about edema in men with heart, kidney or liver disease [1]. In a 30-week open-label randomized comparison of 40 hypogonadal men given testosterone enanthate or testosterone undecanoate, total cholesterol, LDL cholesterol and triglycerides declined over the first 30 weeks while HDL also declined [9].

What happens to your own testosterone production

Testosterone given from outside inhibits pituitary luteinizing hormone, and at large doses also follicle-stimulating hormone, which is how sperm production is suppressed [1]. The withdrawal picture the label describes after supratherapeutic doses includes hypogonadotropic hypogonadism lasting weeks or months [1].

How long until sperm come back

The best data come from healthy men on hormonal contraception, not from men treated for hypogonadism. In an integrated analysis of 30 studies and 1,549 healthy men, median time for sperm concentration to recover to 20 million/mL was 3.4 months; 67% reached that threshold within 6 months, 90% within 12, 96% within 16 and 100% within 24. Recovery was faster with shorter-acting testosterone, shorter treatment, older age and a higher baseline sperm count [2].

In the WHO trial, after injections stopped, the estimated median time from azoospermia to a sperm concentration of at least 20 million/mL was 3.7 months, and to each man's own baseline concentration 6.7 months [4].

For men who have been on testosterone, the numbers are less certain. In a retrospective series of 66 men with infertility after testosterone use who stopped and received high-dose hCG plus a selective estrogen receptor modulator, 46 (70%) reached a total motile count above 5 million within 12 months; 64.8% of men who started azoospermic reached it versus 91.7% of men with cryptozoospermia, and older age and longer testosterone use predicted slower recovery [10].

The label's own wording is modest: oligospermia may occur at high dosages [1], and subfertility and infertility are listed among reactions reported in men who abuse anabolic steroids [1].

Restarting testosterone enanthate

The enanthate label says to confirm hypogonadism with low morning testosterone results on at least two separate days before initiating treatment [1]. The labeled uses are primary hypogonadism (testicular failure) and hypogonadotropic hypogonadism (pituitary or hypothalamic cause); the label states that safety and efficacy in men with age-related hypogonadism have not been established, and FDA has asked for that limitation to be removed (requested June 2026) [1][11].

The Endocrine Society guideline recommends against starting testosterone in men with breast or prostate cancer, an elevated hematocrit, untreated severe sleep apnea, uncontrolled heart failure, or a heart attack or stroke within the previous 6 months [12]. Its earlier guideline put the hematocrit threshold for not starting at above 50% [13].

The enanthate label says that if the drug is restarted after being stopped because of edema (a serious complication in men with cardiac, renal or hepatic disease), a lower dose should be used [1].

Two other label items matter at restart. Testosterone can raise blood pressure, which can raise cardiovascular risk over time; the label says to monitor blood pressure periodically, especially in men with hypertension, and that the product is not recommended in uncontrolled hypertension [1]. And the label still carries the older cardiovascular paragraph: long-term safety trials not conducted, studies inconclusive, some but not all reporting an increased risk of major adverse cardiovascular events [1]. The TRAVERSE trial tested 1.62% testosterone gel, not injections: 5,246 men, major adverse cardiovascular events in 7.0% on testosterone versus 7.3% on placebo, hazard ratio 0.96 [14]. No outcome trial of that size exists for injectable testosterone.

Treatments studied for sperm recovery after testosterone

In 49 men with azoospermia or severe oligospermia while on exogenous testosterone, hCG 3,000 units subcutaneously every other day plus clomiphene, tamoxifen, anastrozole or recombinant FSH restored or improved spermatogenesis in 47 (95.9%), with an average time of 4.6 months and a mean first sperm density of 22.6 million/mL [15]. This was a retrospective case series without a comparison group. The 66-man series above used the same hCG-plus-SERM approach [10].

A review of anabolic steroid-induced hypogonadism lists judicious testosterone replacement, hCG and selective estrogen receptor modulators as management options, notes that the picture depends on dose, duration and type of steroid, and reported that no quality studies met its criteria for meta-analysis [17].